{
    "nct_id": "NCT03226574",
    "official_title": "A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer",
    "inclusion_criteria": "* Histologically confirmed advanced cancer or metastasis, which has not responded to standard therapy, producing intractable chronic pain in any area below the mid-thoracic level.\n* Male or female subjects must be at least 18 years of age.\n* Must have a worst pain score ≥6 on the NPRS at Screening visit.\n* Subjects not seeking or receiving potentially curative therapies for cancer. Palliative therapy is acceptable if the therapy started and is stable prior to IP administration.\n* Sexually active female subjects of childbearing potential and male subjects capable of fathering a child must be willing to use an effective method of contraception to avoid pregnancies.\n* Must be willing and capable of understanding and cooperating with the requirements of the study.\n* Must be able to understand and complete study-related forms and adequately communicate with the investigator and/or site staff.\n* Must have provided written informed consent prior to participating in any study-related activity.\n* Subjects able to complete the study duration.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects with leptomeningeal metastases in lumbar area.\n* Undergoing or have plans to undergo changes to current cancer treatment during the study through the Day15 assessment.\n* Had prior lumbar spine surgical procedures that could impair the ability to perform the injection.\n* Evidence of brain pathology or increase intracranial pressure.\n* Presence of an IT shunt.\n* Has evidence or a coagulopathy or hemostasis problem.\n* Subjects with a total neutrophil count <1500 cells/mm3.\n* Subjects with serum creatinine ≥1.5 mg/dL.\n* Is febrile or has other evidence of an infection within 7 days of planned injection.\n* Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.\n* Female subjects who are pregnant, are planning on becoming pregnant, or are currently breastfeeding.\n* Subjects with any medical condition that could adversely impact study participation or assessments.\n* Subjects who have received new anti-cancer treatments and there is less than one week or four half-lives of the investigational drug, whichever is greater, between the last dose of the new drug and the planned day of IP administration; or had a change in the dose or schedule of the anti-cancer treatments within one week or four half-lives, whichever is greater, between the last dose of the anti-cancer treatment and the planned day of IP administration; or are scheduled to receive a new anti-cancer therapy or investigational product prior to completion of the Day 15 visit.\n* Subjects with additional loci of pain above the mid-thoracic level or other pain disorder due to non-cancer etiology, unless both the investigator and the subject are clearly able to distinguish the additional pain from the target pain due to cancer.\n* Liver cirrhosis or severe hepatic impairment, with liver function test 3 times above ULN.\n* Sensory/peripheral neuropathy of CTCAE Grade 2 or higher.\n* Nonstudy related minor surgical procedure ≤5 days or major surgical procedure ≤21 days prior to Screening visit.\n* Subjects who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, or radiotherapies that are CTCAE Grade 3 or higher.\n* Arterial thrombi (including stroke), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within 3 months prior to Screening visit.\n* Corrected QT using Fridericia's formula (QTcF) prolongation.\n* Evidence or history of bleeding disorder within 4 weeks prior to IP administration.\n* Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.",
    "miscellaneous_criteria": ""
}